Sign in
Taking people in United StatesNo phase

Exoskeleton walking training and sitting balance in people with spinal cord injury

Tests whether exoskeleton walking training improves sitting balance in wheelchair users with spinal cord injury.

Key facts

Who runs it
James J. Peters Veterans Affairs Medical Center
Where
The Bronx, United StatesSee the site
Trial code
Registry title
Seated Balance Using the Indego™
Status
Recruiting
People taking part
20 people, planned
Started
1 Feb 2018
Planned end
31 Dec 2025
Type of study
Interventional
Treatments tested
  • Indego™ Exoskeleton
Record updated
14 May 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with a spinal cord injury at T4 or below who use a wheelchair. They will train walking with the Indego™ exoskeleton, a wearable robotic device, to see if it improves balance while sitting.

Age
18 years and older.
Sex
All sexes can join.
Disease stage
Traumatic or non-traumatic spinal cord injury for at least 6 months. Injury level T4 and below, complete or incomplete (ISNCSCI A to D). Uses a wheelchair indoors and outdoors. Must be able to hold crutches, with or without changes to them.
Earlier treatment
Cannot join if using medicines that lower the seizure threshold, such as tricyclic antidepressants, amphetamines, neuroleptics, dalfampridine and bupropion.
Biomarker or test result
Knee BMD (bone density) must not be below 0.60 gm/cm2. Total hip BMD T-score must not be below -3.5.

Main reasons for not taking part

  • Other nerve injury besides spinal cord injury, a worsening nerve condition, or history of seizure, stroke, brain tumor or multiple sclerosis.
  • Leg fracture from trauma in the past 2 years, any low-impact leg fracture since the injury, or a foot fracture.
  • Body size, stiff joints or ankle limits that do not fit the device.
  • Uncontrolled high blood pressure, or a current pressure sore on the arms, trunk, pelvis or legs.
  • Pregnancy or planning pregnancy, or implants such as a pacemaker, nerve stimulator or metal implants.

The registry criteria, word for word

Show all 27 criteriaShow less

Who can take part

  • Traumatic or non-traumatic SCI ≥6 months duration of SCI
  • Wheelchair-user for indoor and outdoor mobility
  • Level and completeness of injury T4 and below with complete or incomplete SCI (ISNCSCI A to D)
  • Able to hold the crutches in hands with or without modifications; and
  • Able to provide informed consent

Who cannot take part

  • Severe concurrent medical disease, illness or condition judged to be contraindicated by the Site Physician
  • History of moderate or severe head trauma (loss of consciousness for greater than one hour or evidence of brain contusion or hemorrhage or depressed skull fracture on prior imaging)
  • Progressive condition that would be expected to result in changing neurological status
  • Untreated or uncontrolled hypertension (systolic blood pressure >140 mmHg; diastolic blood pressure >90 mmHg)
  • Current pressure ulcer of the arms, trunk, pelvic area, or lower extremities
  • History of seizure
  • Use of medications that significantly lower seizure threshold, such as tricyclic antidepressants, amphetamines, neuroleptics, dalfampridine, and bupropion
  • History of stroke, brain tumor, brain abscess, or multiple sclerosis
  • History of implanted brain/spine/nerve simulators, aneurysm clips, ferromagnetic metallic implants, or cardiac pacemaker/defibrillator
  • Diagnosis of neurological injury other than SCI
  • Anthropocentric incompatibility to be fitted with the device
  • Traumatic or high impact lower extremity fracture within the past 2 years
  • Fragility, minimal trauma or low impact fracture of the lower extremity since spinal cord injury
  • Knee BMD < 0.60 gm/cm2
  • Total hip BMD T-scores < -3.5
  • Untreatable severe spasticity judged to be contraindicated by the Site Physician
  • Flexion contracture that is incompatible with the device
  • Limitations in ankle range of motion that cannot be adapted with an orthotic device (plantar flexion > 00)
  • Fracture of the foot by x-ray and confirmed by CT
  • Unresolved orthostatic hypotension (systolic blood pressure <90 mmHg; diastolic blood pressure <60 mmHg) as judged to be contraindicated by the Site Physician
  • Psychopathology documentation in the medical record or history that may conflict with study objectives; and/or
  • Pregnancy or women who plan to become pregnant during the study period

Where in United States

  • James J Peters VA Medical CenterThe Bronx, United StatesContact: Steven Knezevic, MSTaking people

About the trial

What the trial wants to find out

Exoskeleton-assisted walking (EAW) provides a new mobility option and appears to have potential therapeutic benefits for persons with SCI. However, present day technology is not sufficient to replace the wheelchair. During EAW, users stand upright, maintain static and dynamic balance by actively and passively stimulating trunk and lower limb muscles in a manner not challenged during wheelchair use. Preliminary results in our laboratory suggest that the indirect balance challenges and postural perturbations that result during EAW training transfer to better seated balance control, resulting in more independence during seated activities. The purpose of this pilot study is to determine the effects of EAW training on various measures of seated balance (primary outcomes) and body composition (secondary outcomes). Twenty people with SCI (T4 and below) who are wheelchair users for mobility and cannot walk independently will be recruited. The participants will receive 36 sessions of EAW training in 12 weeks. The outcomes will be evaluated pre (baseline) and post (24 and 36 sessions). If EAW devices can be demonstrated to help people with SCI have better seated balance, in addition to the other potential benefits that are being investigated elsewhere, then exoskeletons may have the possibility to be more readily accepted in the clinical, home environments, and by the insurance companies.

The group in the trial

  • Exoskeleton UsersTreatment being tested

    All participants will receive 36 sessions of supervised EAW training using Indego™ for 12 weeks (3 to 4 sessions per week, 4-6 hours per week). The goal is to complete all 36 sessions in 12 weeks, but allowing for a two-week carryover to accommodate schedule conflicts or missed sessions.

    Treatment: Indego™ Exoskeleton

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
"The Effects of Exoskeletal-Assisted Walking on Seated Balance Using the Indego™"
Plain-language title
Exoskeleton walking training and sitting balance in people with spinal cord injuryGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
14 May 2025